Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-20, Stock:JNJ, The news for the past five days is as follows:
2018-08-13: NEWS1: Jury orders Monsanto to pay $289 million in Roundup cance....NEWS2: Shire, Shionogi File NDA for Intuniv for Adults in Japan.NEWS3: Shire, Shionogi File NDA for Intuniv for Adults in Japan.NEWS4: The Philosophy of Dividend Aristocrat Stocks.NEWS5: Buy Johnson & Johnson, Now Poised to Rally.NEWS6: Shire, Shionogi File NDA for Intuniv for Adults in Japan.NEWS7: CAH Named Top 25 SAFE Dividend Stock Increasing Payments For Decades.NEWS8: CAH Named Top 25 SAFE Dividend Stock Increasing Payments For Decades.NEWS9: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2018.NEWS10: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2018.NEWS11: The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers.NEWS12: The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers.NEWS13: 3 Biotech Stocks With Major Catalysts Incoming.NEWS14: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS15: The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers.
2018-08-14: NEWS1: SurveyMonkey adds Emory dean to board of directors, balancing its gender representation.NEWS2: Better Buy: AbbVie Inc. vs. Johnson & Johnson.NEWS3: Better Buy: AbbVie Inc. vs. Johnson & Johnson.NEWS4: Better Buy: AbbVie Inc. vs. Johnson & Johnson.
2018-08-15: NEWS1: Rare Genetic Mutation May Help Drugmakers Battle Obesity.NEWS2: A Performance Overview of Bausch + Lomb.NEWS3: A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity.NEWS4: Allergan plc. (AGN) Ex-Dividend Date Scheduled for August 16, 2018.NEWS5: Allergan plc. (AGN) Ex-Dividend Date Scheduled for August 16, 2018.
2018-08-16: NEWS1: Notable Thursday Option Activity: AMAT, AIMT, JNJ.NEWS2: Notable Thursday Option Activity: AMAT, AIMT, JNJ.NEWS3: HBJ health care panel talks tech innovation, high patient costs.NEWS4: Trump administration proposes production quota cuts for six opioids.NEWS5: Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?.NEWS6: Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?.NEWS7: A Look at the Performance of Bausch Health’s Ortho Dermatologics.NEWS8: Add Up The Parts: EQWL Could Be Worth $61.NEWS9: Add Up The Parts: EQWL Could Be Worth $61.NEWS10: Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?.NEWS11: Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for August 17, 2018.NEWS12: Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for August 17, 2018.NEWS13: Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation.NEWS14: Should Gilead Be Worried About This New Monthly HIV Medication?.NEWS15: Should Gilead Be Worried About This New Monthly HIV Medication?.NEWS16: Most Analysts Are Optimistic about Vertex Pharmaceuticals.NEWS17: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS18: Should Gilead Be Worried About This New Monthly HIV Medication?.
2018-08-17: NEWS1: The Top UPS Shareholders (UPS).NEWS2: 4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight.NEWS3: 4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight.NEWS4: What Does Baxter International’s Valuation Trend Indicate?.NEWS5: A Closer Look at Allergan’s Business Segments in Q2 2018.NEWS6: Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication.NEWS7: Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication.NEWS8: 4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight.NEWS9: Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication.NEWS10: A Look at Allergan’s Valuation on August 16.NEWS11: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS12: Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS13: Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS14: Glaxo, J&J&apos;s Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS15: New Drugs Approved In July.NEWS16: New Drugs Approved In July.

Answer: Rise